27
Apr

A few years after teaming up with Versant Ventures to get Stanford spinout Quanticel Pharmaceuticals off the ground, Celgene is buying the cancer-focused biotech for up to $485 million.

…read more

Source: Celgene bags a build-to-buy biotech in $485M cancer deal

    

0 No comments